Influence of treatment with an amino oxidase inhibitor on the excretion of bufotenin and the clinical symptoms in chronic schizophrenic patients.
D000328:Adult; D000368:Aged; D002746:Chlorpromazine / Q000627:therapeutic use; D002845:Chromatography; D003295:Convulsive Therapy; D004565:Electroconvulsive Therapy; D006213:Hallucinogens / Q000652:urine*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010624:Phenelzine / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy* / Q000652:urine*; D014268:Trifluoperazine / Q000627:therapeutic use
D006213:Hallucinogens; D014268:Trifluoperazine; D010624:Phenelzine; D002746:Chlorpromazine